EverHint – SMA 20/50 Crossover – Top 5 Buy and Top 5 Sell Signals for Aug 19, 2026
Excerpt: 10 signals (from 22 total). Healthcare leads (8). price range $34-$1033. 1 with insider selling.
What This Signal Is
Detects fresh crossovers between the 20-day simple moving average (SMA20) and the 50-day simple moving average (SMA50). Uses two SMAs, making it more stable and less prone to false signals compared to EMA-based strategies. Well-suited for identifying medium-term trend changes with higher reliability.
Entry Criteria:
- Buy: SMA20 crosses above SMA50
- Sell: SMA20 crosses below SMA50
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh crossover: Detected on today's close
Holding period: 2-6 weeks | Risk level: Medium
Market Context
Equity markets are posting modest but broad-based gains across all three major indices, with the S&P 500, Nasdaq, and Dow Jones each advancing in a tight, synchronized range. This type of narrow, uniform upside movement suggests a low-conviction but steady risk-on environment — conditions that tend to favor trend-following strategies like the SMA20/SMA50 crossover approach. When markets drift higher without sharp intraday reversals, moving average signals have more room to play out cleanly rather than getting whipsawed by volatile price action.
The VIX dropping sharply to 14.89 — a 6% decline in a single session — reinforces the low-volatility backdrop. Compressed volatility typically reduces false signal noise for trend-based systems, as price action becomes more orderly and sustained directional moves are easier to identify. However, traders should remain aware that very low VIX readings can also precede sudden spikes, meaning position sizing and stop discipline remain important even in calm conditions.
Healthcare leading as the top sector among today's signals is a notable rotation cue. Healthcare tends to attract capital during periods of moderate risk appetite — not the aggressive growth-chasing seen in pure bull runs, but a preference for relative stability and defensive growth. This aligns well with the current market tone: investors appear constructive but selective, favoring sectors with earnings visibility over high-beta momentum plays. SMA crossover signals in this sector context may carry a slightly more defensive character, which suits the measured pace of today's broader market advance.
🟢 Buy Signals (5 of 5 total)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | ARGX | argenx SE | Healthcare | $1032.86 | — | $64.2B |
| 2 | CHDN | Churchill Downs Incorp... | Consumer Cyclical | $91.75 | — | $6.4B |
| 3 | HTFL | Heartflow, Inc. Common... | Healthcare | $45.53 | — | $3.9B |
| 4 | LOAR | Loar Holdings Inc. | Industrials | $76.49 | — | $7.2B |
| 5 | MRNA | Moderna, Inc. | Healthcare | $174.38 | — | $69.2B |
🔴 Sell Signals (5 of 17 total)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | ADC | Agree Realty Corporation | Real Estate | $74.41 | — | $8.9B |
| 2 | ALKS | Alkermes plc | Healthcare | $50.18 | Sell -$32,969 | $8.4B |
| 3 | AS | Amer Sports, Inc. | Consumer Cyclical | $34.02 | — | $19.7B |
| 4 | BC | Brunswick Corporation | Consumer Cyclical | $81.61 | — | $5.3B |
| 5 | BLLN | BillionToOne, Inc. | Healthcare | $91.67 | — | $4.2B |
Field Notes
Sector concentration: Healthcare (8), Consumer Cyclical (5), Real Estate (4)
Insider selling (7d): ALKS (Alkermes plc, -$32,969)
Data coverage: 4.5% insider (7d), 0.0% congressional (30d), 0.0% earnings, 9.1% news (7d)
Peer Analysis
ADC (Agree Realty Corporation): Leads 5 peers: NNN ($46.24), BRX ($29.74), FRT ($117.56), FR ($62.76), DLR ($192.35)
Recent Headlines
MRNA (Moderna, Inc.)
- Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For
- Opinion | Moderna's Road to a Cancer Vaccine
- Stock Market Today, Aug. 19: Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data
- Moderna, Merck breakthrough could usher in wave of cancer vaccines
- U.S. Stocks Gain as Treasury Buybacks Calm Bond Yields; Moderna Surges
- Moderna Surges as Stocks Rise & Long-Term Yields Retreat | Closing Bell
- Tempus AI stock is soaring and it has Moderna to thank
- Moderna's cancer-vaccine breakthrough drives broad biopharma stock rally
- Moderna's Cancer Breakthrough Just Made Tempus AI's $1.5 Billion Bet Look Brilliant
Vlad's Take
Today's signals: Strong sector concentration in Healthcare (8 signals) suggests sector-specific rotation.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Support the project by liking, sharing, or subscribing — it helps more readers discover these signals.